Oncotarget ends the year 2016 ranked in the Top 50 oncology journals, as rated by the SCImago Journal & Country Rank. SCImago develops its publicly available rankings from Scopus data. It ranks journals on each scholarly topic. Oncotarget placed 35th of the 322 oncology journals.
Oncotarget, an open-access multidisciplinary peer-reviewed journal, publishes online weekly issues. Its publisher, Impact Journals, says the journal’s ultimate goal is “life without disease.” It tries to help science fulfill that goal by:
– quickly disseminating scientific results,
– providing insightful peer review,
– blurring disciplinary and specialty divides,
– linking the fields of biomedical science,
– fostering application of clinical and basic science in disease control.
Oncotarget’s performance on msubmit.net since its introduction in 2010 encouraged Impact to launch journal sections on topics besides oncology. It opened paper submissions for future sections in the areas of:
– cell & mol biology,
All sections follow the same submission procedures.
The journal features two editors-in-chief, Andrei V. Gudkov and Mikhail V. Blagosklonny, both doctors at the Roswell Park Cancer Institute in Buffalo, NY. Blagosklonny also serves as editor-in-chief of Cell Cycle and as associate editor of Am J Pathology, Autophagy, Cancer Biol Ther, Cancer Res, Cell Death Differ, Int J Cancer, and PLOS ONE. Gudkov co-founded Cleveland BioLabs, Inc. and Tartis, Inc. He focuses his research in the areas of drug discovery, gene discovery, and molecular targets for cancer treatment at http://www.scimagojr.com/journalsearch.php?q=19900191708&tip=sid.
According to BIOXBIO, Oncotarget has an impact factor of 5.008 for 2015/2016 with 10,452 total cites. A journal’s impact factor indicates the frequency of citations of its articles during a given year. A higher impact factor indicates scholarly importance of the journal on researchgate.net. Oncotarget received an impact factor of 4.784 in 2011, the first year it was ranked.